C. Pu

CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study

He Huang, Yi Luo, Jimin Shi, 2018, Annals of Hematology.

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

He Huang, Yi Luo, Jimin Shi, 2016, Journal of Hematology & Oncology.

Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy

He Huang, Jiasheng Wang, Yange Xiao, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice.

Hairuo Wen, Tiantian Hou, Z. Qu, 2019, Annals of translational medicine.

Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus

Linrong Lu, Yongmei Han, Lei Xiao, 2020, Cellular & Molecular Immunology.

Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient

H. Zhang, Y. Luo, J. Shi, 2017, Bone Marrow Transplantation.

Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus

Linrong Lu, Yongmei Han, Lei Xiao, 2020, Cellular & Molecular Immunology.

Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

H. Zhang, He Huang, Z. Cai, 2016, Clinical Cancer Research.

Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia

Qing Zhang, Zhao Wu, Lei Xiao, 2016, Medicine.